A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors
Eli Lilly and Company
Eli Lilly and Company
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Eli Lilly and Company
OncoC4, Inc.
Revolution Medicines, Inc.
USWM, LLC (dba US WorldMeds)
Arcus Biosciences, Inc.
Duke University
Qurient Co., Ltd.
Duke University
Novartis
University Health Network, Toronto
NeoTX Therapeutics Ltd.
Sensei Biotherapeutics, Inc.
Jonsson Comprehensive Cancer Center
Cancer Research UK
OncoC4, Inc.
Tempus AI
University Hospital, Antwerp
Cybrexa Therapeutics
NextCure, Inc.
NGM Biopharmaceuticals, Inc
NGM Biopharmaceuticals, Inc
Adaptimmune